This application seeks renewed CCSG funding for the City of Hope Comprehensive Cancer Center (COHCCC). The COHCCC brings together 131 Members from 34 Departments in the City of Hope Medical Center and the Beckman Research Institute. The Center receives $24,212,096M (Totals) from NCI, $25,947,483M from other peer-reviewed sources, and $31,421,929M from non-peer-reviewed sources, for a total of $81,581,508M in overall funding. Through faculty recruitment, reorganization, and significant infrastructure development, the COHCCC has greatly enhanced its ability to accelerate clinical and translational cancer-focused research. Seventy-two new faculty have been recruited, including 48 clinical investigators and 24 basic and population research scientists. The Cancer Center has five Programs: Molecular Oncology (MONC), Developmental Cancer Therapeutics (DCT), Cancer Immunotherapeutics (CI), Hematologic Malignancies (HM), and Cancer Control and Population Sciences (CCPS). Center membership has been honed to sharpen cancer focus and an Associate Member category has been created for investigators whose potential for peer-reviewed, cancer-focused research is yet developing. This application requests support for ten Shared Resources: Analytical Cytometry, Analytical Pharmacology, Bioinformatics, Functional Genomics/Genomic Sequencing, Pathology, Small Animal Imaging, Drug Discovery and Structural Biology, Survey Research, Biostatistics, and Clinical Protocol and Data Management. The COHCCC is primed to make significant advances in the coming years. Our 72 new basic, population and clinical research recruits will continue to introduce new ideas, technologies, and areas of research focus while enhancing the creative and innovative environment of the Center. Significant infrastructure and other resources have been created to facilitate the translation of discoveries to the rapid development of new cancer treatments, diagnostic tests, and other interventions that would aid people with cancer, as well as individuals at risk for malignancy. Finally, the overall configuration of the institution and its administrative capabilities in terms f leadership, programmatic alignment, development, and authority that have been augmented so that the Cancer Center will be more responsive to its members and to harness their collective energies and creativity. This proposal documents that the COHCCC has built a solid structure for achieving its missions and is stronger and more sustainable than it has ever been.

Public Health Relevance

; Organizational capabilities under the authority of the Cancer Center Director are key for appropriate leadership, evaluation and planning. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
4P30CA033572-33
Application #
8975121
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2017-11-30
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
33
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Liu, Xuxiang; Cao, Minghui; Palomares, Melanie et al. (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127
Das, Sadhan; Reddy, Marpadga A; Senapati, Parijat et al. (2018) Diabetes Mellitus-Induced Long Noncoding RNA Dnm3os Regulates Macrophage Functions and Inflammation via Nuclear Mechanisms. Arterioscler Thromb Vasc Biol 38:1806-1820
Querfeld, Christiane; Leung, Samantha; Myskowski, Patricia L et al. (2018) Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6:900-909
Chiuppesi, Flavia; Nguyen, Jenny; Park, Soojin et al. (2018) Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice. J Virol 92:
Petrossian, Karineh; Kanaya, Noriko; Lo, Chiao et al. (2018) ER?-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget 9:27736-27751
Al Malki, Monzr M; Nathwani, Nitya; Yang, Dongyun et al. (2018) Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1828-1835
Bosworth, Alysia; Goodman, Elizabeth L; Wu, Eric et al. (2018) The Minneapolis-Manchester Quality of Life Instrument: reliability and validity of the Adult Form in cancer survivors. Qual Life Res 27:321-332
Vu, Binh Thanh; Shahin, Sophia Allaf; Croissant, Jonas et al. (2018) Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep 8:8524
Ambaye, Nigus; Chen, Chih-Hong; Khanna, Swati et al. (2018) Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1? (HIF1?) in Cells. Biochemistry 57:1807-1813
Li, Sihui; Ali, Shafat; Duan, Xiaotao et al. (2018) JMJD1B Demethylates H4R3me2s and H3K9me2 to Facilitate Gene Expression for Development of Hematopoietic Stem and Progenitor Cells. Cell Rep 23:389-403

Showing the most recent 10 out of 1396 publications